Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response to ...

The FDA granted fast track designation to AUTX-703 for the treatment of patients with relapsed/refractory acute myelogenous leukemia (R/R AML). Preclinical studies demonstrated dose-dependent survival ...

aHuman Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA bLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer ...

Understanding the fundamental molecular mechanisms underlying normal hematopoiesis and AML pathogenesis can aid the development of novel and effective targeted therapies. Prof. Wang concludes by ...

The main focus of our research is to discover factors and pathways that represent potential drug targets in AML and to delineate the underlying molecular mechanisms by which they are involved in ...

it is above all the perturbation of the RUNX1 gene -- a gene that regulates many other genes -- that seems to be responsible for AML pathogenesis. Targeting the perturbed regulator could pave the ...

An established oncogenic driver of AML pathogenesis is the FLT3 protein, which previous work has shown to be frequently mutated in AML cells. Additional work has also found that PRL2 is highly ...

We identified a potential driver oncogenic role in the loss of expression of both miR-15/16 clusters in the progression of MDS into AML and in AML pathogenesis. The stratification of AML patients, ...